Filtered By:
Infectious Disease: Herpes
Therapy: Immunotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 156 results found since Jan 2013.
Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
This study aimed to investigate whether the therapeutic benefits of tumor-targeting Claudin18.2 BiTE can be augmented by combining cancer selectively and immune-potentiating effects of OVs. Claudin18.2/CD3 BiTE was inserted into herpes simplex virus type 1 (HSV-1) to construct an OV-BiTE. Its expression and function were assessed using reporter cells and peripheral blood mononuclear cell (PBMC) co-culture assays. Intratumoral application of OV-BiTE restrained tumor growth and prolonged mouse survival compared with the unarmed OV in xenograft models and syngeneic mice bearing CLDN18.2-expressing KPC or Pan02 pancreatic canc...
Source: Herpes - September 13, 2023 Category: Infectious Diseases Authors: Shiyu Liu Fan Li Li Deng Qiongqiong Ma Wenyi Lu Zhuoqian Zhao Huanzhen Liu Yixuan Zhou Manli Hu Hui Wang Yingbin Yan Mingfeng Zhao Hongkai Zhang Mingjuan Du Source Type: research
Anti-NMDAR encephalitis secondary to acute necrotizing encephalopathy caused by herpes simplex virus infection in infants: Case series
CONCLUSION: Infants with ANE associated with HSV can develop secondary anti-NMDAR encephalitis, recognition of which is critical to ensure the appropriate institution of immunotherapy after active CNS infection has been ruled out.PMID:37689014 | DOI:10.1016/j.clineuro.2023.107955
Source: Herpes - September 9, 2023 Category: Infectious Diseases Authors: Jia Zhang Jinfeng Liu Jianjun Wang Jing Gan Source Type: research
Interferon inhibits the release of herpes simplex virus-1 from the axons of sensory neurons
In this study, we determined the effects of type I, II, and III IFNs on HSV-1 release from sensory axons. Using compartmentalized microfluidic devices separating axons from the neuronal cell bodies, we showed that treating axons with type I (IFNα and IFNβ), type II (IFNγ), and type III (IFNλ) IFNs inhibited the release of HSV-1 from axons, without altering the anterograde axonal transport of viral components. Furthermore, we showed that only type II IFN induced a cell-wide response following axonal treatment, with phosphorylated STAT1 and STAT3 present along axons and in the neuronal cell body, whereas type I and III I...
Source: Herpes - September 1, 2023 Category: Infectious Diseases Authors: Kevin Danastas Gerry Guo Jessica Merjane Nathan Hong Ava Larsen Monica Miranda-Saksena Anthony L Cunningham Source Type: research
Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies
Expert Rev Anti Infect Ther. 2023 Aug 15:1-13. doi: 10.1080/14787210.2023.2247161. Online ahead of print.ABSTRACTINTRODUCTION: Kaposi sarcoma herpes virus (KSHV) is associated with several diseases including Kaposi sarcoma, a form of multicentric Castleman's disease, primary effusion lymphoma, and an inflammatory cytokine syndrome. These KSHV-associated diseases (KAD) can present with heterogenous signs and symptoms that are often associated with cytokine dysregulation that may result in multiorgan dysfunction. The inability to promptly diagnose and treat these conditions can result in long-term complications and mortality...
Source: Expert Review of Anti-Infective Therapy - August 14, 2023 Category: Infectious Diseases Authors: Roshani Patel Kathryn Lurain Robert Yarchoan Ramya Ramaswami Source Type: research
OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment
Conclusion: OV-mOX40L converted the immunosuppressive tumor immune microenvironment to a more activated state, remodeled the stromal matrix, and enhanced T cell response. OV-mOX40L significantly prolonged the survival of PDAC mice, either as a monotherapy or in combination with synergistic antibodies. Thus, this study provides a multimodal therapeutic strategy for pancreatic cancer treatment.PMID:37554264 | PMC:PMC10405835 | DOI:10.7150/thno.83495
Source: Herpes - August 9, 2023 Category: Infectious Diseases Authors: Shiyu Liu Fan Li Qiongqiong Ma Mingjuan Du Haoran Wang Yiping Zhu Li Deng Wenrui Gao Chunlei Wang Yanqin Liu Zhuoqian Zhao Huanzhen Liu Ruikun Wang Yujie Tian Manli Hu Yajuan Wan Wenyi Lu Meng Zhang Mingfeng Zhao Youjia Cao Hongkai Zhang Wei Wang Hui Wang Source Type: research
The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy
Cureus. 2023 Jun 21;15(6):e40742. doi: 10.7759/cureus.40742. eCollection 2023 Jun.ABSTRACTA promising future for oncology treatment has been brought about by the emergence of a novel approach utilizing oncolytic viruses in cancer immunotherapy. Oncolytic viruses are viruses that have been exploited genetically to assault malignant cells and activate a robust immune response. Several techniques have been developed to endow viruses with an oncolytic activity through genetic engineering. For instance, redirection capsid modification, stimulation of anti-neoplastic immune response, and genetically arming viruses with cytokines...
Source: Herpes - July 24, 2023 Category: Infectious Diseases Authors: Mohammed A Zolaly Waleed Mahallawi Zakaria Y Khawaji Mohammed A Alahmadi Source Type: research
